Скачать или смотреть PSA Screening: Reducing Prostate Cancer Deaths and Improving Safety

Discover the latest findings from the 23-year ERSPC trial on prostate cancer screening. This study reveals that regular and protocolized PSA testing significantly lowers prostate cancer mortality and enhances the benefit-to-harm ratio. Learn how this research supports a move towards personalized screening strategies based on individual risk factors.
The European Study of Prostate Cancer Screening (ERSPC) trial provides compelling evidence for the effectiveness of PSA screening in improving survival rates. By analyzing data from thousands of men over two decades, researchers found that sustained PSA testing can make a real difference in prostate cancer outcomes. The study also addresses concerns about overdiagnosis and unnecessary treatments, offering insights into optimizing screening policies.
Key takeaways from the video:
ERSPC trial results show a 13% relative reduction in prostate cancer deaths with PSA screening.
Protocolized screening improves the balance between benefits and potential harms.
Risk-based screening intervals and stopping rules can minimize overdiagnosis and overtreatment.
Shared decision-making, risk calculators, and MRI can enhance patient-centered care.
Targeted screening aligns with patient priorities while reducing unnecessary procedures.